Active, not recruitingPhase 2NCT06260709

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Studying Amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novo Nordisk A/S
Principal Investigator
Clinical Transparency (dept. 2834)
Novo Nordisk A/S
Intervention
NNC6019-0001(drug)
Enrollment
80 enrolled
Eligibility
18-85 years · All sexes
Timeline
20242028

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06260709 on ClinicalTrials.gov

Other trials for Amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for Amyloidosis

← Back to all trials